VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AXGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AXGNAxoGen, Inc.
$56.95$3.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
AXGN logo

AxoGen, Inc.

AXGN
NASDAQ · Medical Devices
$56.95
At close - Nov 18, 4:00 PM EST - USD
Market Cap$3.06B
P/E-109.8x
52W High$59.72
Volume2.11M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Momentum Meets Thin Profitability and Cash Build

AxoGen's top line has sustained growth near 23% to 27% over the last three quarters, reaching $75.8M in 2026Q3, and its gross margin of roughly 72% to 77% suggests the proprietary processing advantage remains intact as volume scales.

GrowthExpanding
ProfitabilityStrained
ValuationExpensive
TechnicalsStrong
Explore valuation models
MARKET ACTION

AXGN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-469% Peers

P/E is 469% below peer median

03

Market leadership

RS 95 · Leader

High momentum (Outperforming 95% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Jan 28

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
AXGN+83.71%
S&P 500 (^GSPC)+6.88%
1-Year Return
AXGN+137.19%
S&P 500 (^GSPC)+10.62%
3-Year Return
AXGN+841.32%
S&P 500 (^GSPC)+60.64%
5-Year Return
AXGN+462.19%
S&P 500 (^GSPC)+80.30%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-109.8x
Forward P/E
102.7x
EV/EBITDA
N/A
FCF YieldCash Flow
0.5%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-109.8x
N/A
N/A
EV/EBITDA
N/A
169.3x
N/A
Price/FCF
187.7x
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$0.76-98.7%
Base (Fair)$40.65-27.3%
Bull$1.51-97.3%
$0.76 Bear$40.65 Base$1.51 Bull
Current Market Price: $56.95
Trades at a 40.1% premium to Base DCF ($40.65)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$225M+20.2% YoY
Net income FY25
-$16M-57.6% YoY
Free cash flow FY25
-$3M-26763.6% YoY
Operating margin FY25
-3.5%-1.7 pts YoY
ROIC (FY25)-3.8%
Avg ROIC 5Y-9.1%
ROE (TTM)-11.3%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate9/12 (75%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 28, 2026
$0.21+59.9%
vs $0.13
$76M+3.2%
vs $73M
Q3 2026
Jul 29, 2026
$0.12-1.2%
vs $0.12
$70M+3.9%
vs $67M
Q2 2026
Apr 28, 2026
$0.07-41.7%
vs $0.12
$61M+6.2%
vs $58M
Q1 2026
Feb 24, 2026
$0.07-21.2%
vs $0.09
$60M+1.5%
vs $59M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Nov 9, 2026
Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript

Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript

GlobeNewsWire·Nov 3, 2026
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:

Zacks Investment Research·Nov 2, 2026
GMED vs. AXGN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for undervalued stocks?

Seeking Alpha·Oct 30, 2026
Axogen: Taking The Friction Out Of Nerve Repair

Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45% adjusted EBITDA growth, and operating leverage outpacing dilution, with guidance for at least $290M in 2026 sales and 73%+ gross margin. The $200M BioCircuit (NerveTape) acquisition eliminates technical barriers for surgeons, expands the addressable market, and is accretive at 5.9x expected 2027 sales.

Filtered for AxoGen, Inc.More Headlines
04

Compare before deciding

Benchmark AXGN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for AxoGen, Inc. (AXGN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
AXGN logoAXGNAxoGen, Inc.Current
$56.95$3.06B-109.7720.21%-11.96%-11.34%—
TELA logoTELATELA Bio, Inc.
$0.78$34.9M-1.0715.84%-53.57%——
NVCR logoNVCRNovocure Ltd
$10.73$1.24B-10.298.28%-16.78%-35.81%—
XTNT logoXTNTXtant Medical Holdings, Inc.
$0.21$28.87M6.8614.21%-15.92%-36.21%—
MDXG logoMDXGMiMedx Group, Inc.
$3.18$463.52M-24.1619.99%-6.32%-8.29%—
ANIK logoANIKAnika Therapeutics, Inc.
$13.62$182.28M-103.26-5.91%-1.43%-1.28%—

Compare AXGN vs Peers

AxoGen, Inc. (AXGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TELA

Most directly comparable listed peer for AXGN.

Scale Benchmark

vs ISRG

Larger-name benchmark to compare AXGN against a more recognizable public peer.

Peer Set

Compare Top 5

vs TELA, NVCR, XTNT, MDXG

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

AXGN SEC Filings & Documents

AxoGen, Inc. (AXGN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 28, 2026·SEC

Material company update

Oct 1, 2026·SEC

Material company update

Jul 29, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Mar 5, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 28, 2026·SEC

FY 2026

Jul 29, 2026·SEC

FY 2026

Apr 28, 2026·SEC

Get notified when AXGN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

AXGN Frequently Asked Questions

AxoGen, Inc. (AXGN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is AxoGen, Inc.'s revenue?

AxoGen, Inc. (AXGN) reported $266.9M in revenue over the trailing twelve months. Revenue was $225.2M in fiscal year 2025. That is 1619% more than the $13.1M of fiscal year 1996.

How fast is AxoGen, Inc. growing?

AxoGen, Inc. (AXGN) grew revenue by 24.3% over the trailing twelve months, compared with the twelve months before.

Is AXGN profitable?

No. AxoGen, Inc. (AXGN) reported a net loss of $31.9M over the trailing twelve months.

Dividend & Returns
What is AXGN's return on equity?

AxoGen, Inc. (AXGN) had a return on equity (ROE) of -11.3% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is AxoGen, Inc.'s free cash flow?

AxoGen, Inc. (AXGN) generated $16.3M in free cash flow over the trailing twelve months.

What if you invested $1,000 in AXGN back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →